GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (NAS:YTEN) » Definitions » Operating Margin %

Yield10 Bioscience (Yield10 Bioscience) Operating Margin % : -5,411.67% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Yield10 Bioscience's Operating Income for the three months ended in Dec. 2023 was $-3.25 Mil. Yield10 Bioscience's Revenue for the three months ended in Dec. 2023 was $0.06 Mil. Therefore, Yield10 Bioscience's Operating Margin % for the quarter that ended in Dec. 2023 was -5,411.67%.

Warning Sign:

Yield10 Bioscience Inc operating margin has been in a 5-year decline. The average rate of decline per year is -61.9%.

The historical rank and industry rank for Yield10 Bioscience's Operating Margin % or its related term are showing as below:

YTEN' s Operating Margin % Range Over the Past 10 Years
Min: -24028.33   Med: -1134.57   Max: -884.21
Current: -12014.17


YTEN's Operating Margin % is ranked worse than
99.58% of 237 companies
in the Agriculture industry
Industry Median: 5.44 vs YTEN: -12014.17

Yield10 Bioscience's 5-Year Average Operating Margin % Growth Rate was -61.90% per year.

Yield10 Bioscience's Operating Income for the three months ended in Dec. 2023 was $-3.25 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.42 Mil.


Yield10 Bioscience Operating Margin % Historical Data

The historical data trend for Yield10 Bioscience's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yield10 Bioscience Operating Margin % Chart

Yield10 Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,066.50 -1,202.63 -1,904.23 -2,989.11 -24,028.33

Yield10 Bioscience Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -712.00 -6,333.33 - - -5,411.67

Competitive Comparison of Yield10 Bioscience's Operating Margin %

For the Agricultural Inputs subindustry, Yield10 Bioscience's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yield10 Bioscience's Operating Margin % Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Yield10 Bioscience's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Yield10 Bioscience's Operating Margin % falls into.



Yield10 Bioscience Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Yield10 Bioscience's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-14.417 / 0.06
=-24,028.33 %

Yield10 Bioscience's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-3.247 / 0.06
=-5,411.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yield10 Bioscience  (NAS:YTEN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Yield10 Bioscience Operating Margin % Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Yield10 Bioscience (Yield10 Bioscience) Business Description

Traded in Other Exchanges
Address
19 Presidential Way, Woburn, MA, USA, 01801
Yield10 Bioscience Inc is an agricultural bioscience company. It focuses on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. The company uses two proprietary advanced biotechnology trait gene discovery platforms to improve fundamental crop yield through enhanced photosynthetic carbon capture and increased carbon utilization efficiency to increase seed yield. Having developed various crops, such as Camelina, canola, soybean, and corn, the firm concentrates to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton director 1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser officer: VP Fin and CAO
Lynne H Brum officer: VP Planning and Comms 21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell officer: VP Research & CSO C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey director C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples director, officer: Pres & CEO C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin director 21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully 10 percent owner C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038

Yield10 Bioscience (Yield10 Bioscience) Headlines

From GuruFocus